Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines

Journal of Gastroenterology

Volumn 48, Issue 4, 2013, Pages 535-543

  Harada, Naoki ^a   Hiramatsu, Naoki ^a   Oze, Tsugiko ^a   Yamada, Ryoko ^a   Kurokawa, Mika ^a   Miyazaki, Masanori ^a   Yakushijin, Takayuki ^a   Miyagi, Takuya ^a   Tatsumi, Tomohide ^a   Kiso, Shinichi ^a   Kanto, Tatsuya ^a   Kasahara, Akinori ^a   Oshita, Masahide ^b   Mita, Eiji ^c   Hagiwara, Hideki ^d   Inui, Yoshiaki ^e   Katayama, Kazuhiro ^f   Tamura, Shinji ^g   Yoshihara, Harumasa ^h   Imai, Yasuharu ⁱ   Inoue, Atsuo ^j   Hayashi, Norio ^d   Takehara, Tetsuo ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e Hyogo Prefectural Nishinomiya Hospital   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g Minoh City Hospital   (Japan)

^h OSAKA ROSAI HOSPITAL   (Japan)

ⁱ Ikeda Municipal Hospital   (Japan)

^j OSAKA GENERAL MEDICAL CENTER   (Japan)

more..

Author keywords

Cumulative carcinogenesis rate; Hepatitis C virus; Normal alanine aminotransferase; Pegylated interferon plus ribavirin combination therapy; Treatment guidelines

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CANCER INCIDENCE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; JAPANESE; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING; AGED; BLOOD; DRUG COMBINATION; ENZYME ASSAY; INCIDENCE; JAPAN; LIVER TUMOR; METHODOLOGY; MULTICENTER STUDY; PATIENT SELECTION; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STANDARD; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CLINICAL ENZYME TESTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET COUNT; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84886470651     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0657-1     Document Type: Article

References (30)

1. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112: 463-72.
2. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27: 1435-40.
3. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29: 1311-6.
4. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology. 2002;123: 2082-99.
5. Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med. 2000;109: 62-4.
6. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl 1): 9-16.
7. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, et al. Prospective study on antihepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology. 2001;34: 1000-5.
8. Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R, Colombo E, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology. 1998;27: 853-6.
9. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36: 973-7.
10. Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol. 1999;31(Suppl 1): 193-6.
11. Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21: 406-12.
12. Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther. 2006;23: 777-85.
13. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-56.
14. Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, et al. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. J Gastroenterol. 2011;46(11): 1335-43.
15. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127: 1724-32.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24: 289-93.
17. Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study. J Gastroenterol Hepatol. 2001;16: 536-40.
18. Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis. 2000;32: 634-43.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49: 1335-74.
20. Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis. 2003;35: 362-9.
21. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26: 1393-8.
22. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol. 2009;50: 729-35.
23. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-82.
24. Puoti C, Bellis L, Martellino F, Guarisco R, Dell' Unto O, Durola L, Galossi A. Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test. J Hepatol. 2005;43: 534-5.
25. Puoti C, Bellis L, Galossi A, Guarisco R, Nicodemo S, Spilabotti L, Unto OD. Antiviral treatment of HCV carriers with persistently normal ALT levels. Mini Rev Med Chem. 2008;8: 150-2.
26. Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, Yasui K, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005;43: 599-605.
27. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137: 1-10.
28. Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology. 2004;126: 1409-15.
29. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-65.
30. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140: 346-55.